PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective

Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as antineoplastic agent >20 years ago, only a few phase III randomized trials have shown challenging data regarding different therapeutic options for facing its aggressive clinical course and granting activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Loizzi, Vera, Ranieri, Girolamo, Laforgia, Mariarita, Gadaleta, Cosmo Damiano, Gargano, Giulio, Kardhashi, Anila, De Liso, Maria, Naglieri, Emanuele, Del Vecchio, Vittoria, Cicinelli, Ettore, Cormio, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439101/
https://www.ncbi.nlm.nih.gov/pubmed/32831909
http://dx.doi.org/10.3892/ol.2020.11951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439101/
https://www.ncbi.nlm.nih.gov/pubmed/32831909
http://dx.doi.org/10.3892/ol.2020.11951

Ejemplares similares